Xcout IntelRege Nephro
Rege Nephro Co., Ltd. is a biotechnology company headquartered at Kyoto University in Kyoto, Japan. The company engages in medical-pharmaceutical collaborative research and advanced therapeutic development for kidney and regenerative medicine.
Subscribe to see Rege Nephro’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Rege Nephro at a glance
Rege Nephro is a drug discovery company headquartered in Japan. It has raised at least $77M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $62M in July 2026. Xcout tracks 15 named people at Rege Nephro, including Akifumi Morinaka (Representative Director and CEO).
Rege Nephro leadership
- Akifumi MorinakaRepresentative Director and CEO
- 山口 勝久取締役/CFO 管理本部長
- 森中 紹文代表取締役CEO
- 長船 健二最高科学顧問（創設者） 京都大学iPS細胞研究所教授
- 中野 毅執行役員 研究開発本部長
- 小林 義史執行役員 生産本部長
9 more named people on record for Rege Nephro, with roles, board committees and tenure — see the full roster →
Rege Nephro funding rounds
At least $77M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $62M | 14 named | |
| Series B | $15M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Rege Nephro competitors
A few of Rege Nephro's closest competitors — see the full list of competitors and alternatives →
Kringle Pharma, Inc. is a late-stage regenerative drug discovery bio-venture located in Shinsenrihigashimachi, Osaka, Japan. The company operates in the biotechnology and manufacturing sectors.
Renibus Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Southlake, Texas, dedicated to transforming outcomes in specialty therapeutics and disease treatments.
iRegene Therapeutics is a biotechnology company headquartered in Wuhan, China, with additional facilities in Suzhou. The firm specializes in regenerative medicine and advanced cell therapies designed to redefine modern medicine.
Alebund Pharmaceuticals is a biopharmaceutical company founded in early 2018 in Shanghai, China, with operations also in Yangzhou City, focusing on the discovery and development of treatments for kidney disease.
Cellusion Inc. is a regenerative medicine company headquartered in Chuo, Tokyo, Japan. The company focuses on regenerating human potential and maintains its headquarters in the Nihonbashi-Harumi area to foster close community and business connections.
Sarcomatrix Therapeutics Corp. is a biopharmaceutical and biotechnology research company headquartered in Reno, Nevada. The company is dedicated to pioneering muscle regeneration therapies and advancing novel therapeutics to treat muscle-wasting diseases.
Get Rege Nephro's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Rege Nephro in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access